Read our latest ongoing research as we work to advance the standards of care in our therapeutic areas of focus.
Serdexmethylphenidate/Dexmethylphenidate Capsules for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): A Plain Language Summary
Kollins SH, et al. Future Neurology. 2023; 0026. doi: 10.2217/fnl-2023-0026
View PublicationSerdexmethylphenidate/Dexmethylphenidate for Children with Attention-Deficit/Hyperactivity Disorder: Dose Optimization from a Laboratory Classroom Study
Cutler AJ, et al. Front Psychiatry. 2024; 15, 1310483. doi: 10.3389/fpsyt.2024.1310483
View PublicationA Study of Once-a-Week Donepezil Transdermal System's Bioequivalence to Oral Donepezil in Healthy Volunteers: A Plain Language Summary
Braeckman R, et al. Neurodegen Dis Manage. 2023. doi: 10.2217/nmt-2023-0012
View PublicationSerdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
Mattingly GW, et al. Front Psychiatry. 2023. 14:1193455. doi: 10.3389/fpsyt.2023.1193455
View PublicationAnalysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate
Childress AC, et al. J Child Adolesc Psychopharmacol. May 2023.134-142. doi: 10.1089/cap.2023.0012
View PublicationComparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil
Tariot PN, et al. J Alzheimers Dis. 2022;90(1):161-172. doi: 10.3233/JAD-220530
View PublicationSafety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study
Childress AC, et al. J Child Adolesc Psychopharmacol. 2023. doi: 10.1089/cap.2022.0076
View PublicationDose-Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate (SDX)/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder
Braeckman R, et al. J Child Adolesc Psychopharmacol. 2022. doi: 10.1089/cap.2022.0015
View PublicationOral, Intranasal, and Intravenous Abuse Potential of Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate
Shram MJ, et al. Curr Med Res Opin. 2022;38(7);1237-1250. doi: 10.1080/03007995.2022.2076474
View PublicationA Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder
Kollins SH, et al. J Child Adolesc Psychopharmacol. 2021;31(9):597-609
View PublicationA Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System
Sabbagh M, et al. Presentation. CTAD 2022
View PresentationA Retrospective Real-World Analysis Demonstrating the Value of AZSTARYS for Patients With Attention-Deficit Hyperactivity
Faraone S, et al. Presentation. Psych Congress 2022
View PresentationBioequivalence and Safety Comparison of Once-Weekly Donepezil Transdermal System With Oral Donepezil: Results of a Phase 1 Pharmacokinetic Study in Healthy Volunteers
Tariot P, et al. Presentation. AAIC 2022
View PresentationDose Proportionality and Effects of Food on the Pharmacokinetics of Single-Entity Serdexmethylphenidate
Braeckman R, et al. Presentation. APSARD 2022
View PresentationEvaluation of Skin Adhesion and Local Skin Tolerability of Once-Weekly Donepezil Transdermal System: Results of a Phase 1 Trial in Healthy Volunteers
Tariot P, et al. Presentation. Psych Congress 2022
View PresentationMass Balance and Metabolic Pathway Following Oral Administration of [14C]-Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate
Braeckman R, et al. Presentation. APSARD 2022
View PresentationSerdexmethylphenidate/Dexmethylphenidate for Children With Attention-Deficit Hyperactivity Disorder: Reduction in Disorder Severity From a Laboratory Classroom Study
Childress A, et al. Presentation. Psych Congress 2022
View PresentationSerdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder
Mattingly G, et al. Presentation. Psych Congress 2022
View PresentationSerdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study
Oh C, et al. Presentation. CHADD 2021
View PresentationSerdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study
Oh C, et al. Presentation. American Psychiatric Nurses Association 2021
View PresentationSingle-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight
Braeckman R, et al. Presentation. AACAP 2021
View PresentationSteady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate
Braeckman R, et al. Presentation. Psych Congress 2021
View Presentation